Are you a life science SME ready to stay ahead in the rapidly evolving skills landscape? Join industry leaders, experts, and like-minded innovators for this exclusive webinar designed to equip you with insights and practical strategies around talent development.
Agenda Highlights include:
• First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases
• NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target
• Inhibition of the mPTP in the brain prevents neuronal cell death and reduces neuroinflammation in animals
• $5M grant from The Michael J. Fox Foundation (MJFF) to advance NRG5051 into the clinic
For researchers looking to optimize protocols for cell culture and differentiation of ES/iPS cells - AMSBIO has introduced the iMatrix Palette. This new kit containing all variants of their iMatrix recombinant laminin E8 fragment isoforms** saving researchers time, cost, and improving reproducibility.
London, October 28, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for ArcticZymes Technologies ASA (OSE: AZT) and is pleased to announce the placement of Dr. Frank Mathias as Chair of the Board.
This is an exciting opportunity to get involved in a research project building upon innovative AI approaches to define gene x drug exposure x phenotype relationships at scale over continuous time in large human cohorts. We are looking for a highly motivated bioinformatics expert or data scientist to join this exciting project, and to drive specific aspects of this cutting-edge research, including the analysis of population scale genetic cohorts with electronic healthcare and prescriptions records.
Water is a critically important, but often overlooked, component of molecular recognition in proteins. An ability to analyze water accurately has many benefits in the understanding and prediction of drug-protein interactions.
Following the success of this year’s Awards, with feedback indicating it brought something new and inclusive to the ecosystem, One Nucleus is delighted to announce our Annual Awards 2025.
The continued success of the Life Sciences sector is built on the excellence of all its stakeholders hence One Nucleus feels we should celebrate by recognising all parts of our community including life science innovators, R&D companies, non-profit organisations, technical providers and professional advisors.
Our Strategic Partnership with RESI London: What It Means For You
An exciting opportunity to lead the Operations Team at Stevenage Bioscience Catalyst, an award-winning location for companies to start-up, scale-up and commercialise therapeutic innovations in the centre of the golden triangle.
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst co-located on the Elevate Quarter Campus in Stevenage with a focus on providing accommodation and support to help companies develop and commercialise cutting edge therapeutics.
Funding from Anglia Ruskin University is helping small firms' cutting-edge initiatives
Virtual reality therapy for people suffering from mental health disorders, using AI to manage demand on NHS services, and technology that listens to a child’s cough to assist early diagnoses are among the Essex innovations that have received thousands of pounds of funding from Arise Innovation Hubs – part of Anglia Ruskin University (ARU).